In late April, researchers at the University of Kansas Medical Center published results from the first-ever pilot trial of creatine monohydrate in patients with early-stage Alzheimer’s. Over eight weeks, the supplement — the same white powder sold in tubs at Costco for twenty bucks — was associated with improved cognitive function and a roughly 30% slowing of decline relative to baseline, alongside measurable increases in brain phosphocreatine levels.

The study was small. Non-blinded. Preliminary. All the standard caveats apply, and the authors were careful to issue them. But the finding still landed with enough force to light up Hacker News this week and spend days bouncing around group chats where people have parents entering the long dusk.

A cheap, widely available, well-understood compound — studied since the 1990s for muscle performance, safety profile exhaustively mapped — might meaningfully slow the disease that terrifies Americans more than cancer and stroke combined. You’d expect a parade of press releases from every pharmaceutical communications department in New Jersey.

You’d be wrong.

The silence has been instructive.

The Patent Cliff Nobody Wants to Climb

Creatine monohydrate is unpatentable. It’s been generic for decades. Any manufacturer can produce it. A month’s supply at the studied dose — roughly five grams daily — runs about fifteen dollars. That is not a typo. Fifteen dollars. For a condition where the FDA-approved biologics, aducanumab and lecanemab, carry list prices in the tens of thousands per year, require infusion centers, and come with amyloid-related imaging abnormalities that terrify prescribing neurologists.

The economics are perverse in exactly the way that shapes which molecules get Phase III funding. A pharma company that spends $200 million on a large randomized trial for creatine sees zero exclusivity on the back end. Every competitor fills capsules the day results publish. The NIH, in theory, could fund it — but the agency’s Alzheimer’s budget tilts heavily toward amyloid and tau pathways, the hypotheses around which entire academic careers have been constructed. Repurposing a gym supplement doesn’t win anyone a Lasker.

One researcher involved in nutritional psychiatry, who corresponded over Slack while reviewing the Kansas data, put it bluntly: “There is no champion for creatine inside the funding apparatus. No KOL owns it. No biotech is building a slide deck. It’s an orphan in plain sight.”

What Gets Funded vs. What Gets Studied

The amyloid hypothesis has consumed something like $40 billion in research spending over three decades. It has produced drugs that modestly clear plaques and generate contentious debates about whether the clinical benefits justify the risks. Reasonable people can disagree about lecanemab’s risk-benefit profile. What’s harder to defend is a funding architecture where a $15 generic with a clean safety record and a plausible mechanism — Alzheimer’s involves impaired cerebral energy metabolism, and creatine directly addresses that — languishes at the pilot stage while the seventh anti-amyloid monoclonal antibody racks up billion-dollar trial costs.

This isn’t a conspiracy. It’s an emergent property of a system where the incentives point toward molecules that can be protected with composition-of-matter patents. Nobody sat in a boardroom and decided to suppress creatine research. They simply declined to write checks for something that couldn’t produce a return. The outcome is the same either way: a promising signal sits in a small Kansas study while families wait.

The Hacker News thread on the study drew 244 points and 172 comments, many of them variations on “my dad has been taking creatine for years and his cognition hasn’t declined” — anecdotes, not data, but the volume of them points to something real. People are already experimenting, with or without the medical establishment’s blessing. A compounding pharmacist in Ohio told me last week that she’s had four requests this month to formulate creatine for elderly patients whose children read about the Kansas results.

The Real Regulatory Failure Nobody Talks About

When regulatory critics complain about the FDA, the complaints usually center on the agency being too slow or too cautious. The creatine story suggests a different failure mode: the gap between what the market will fund and what actually warrants studying. The FDA can approve or reject what’s put in front of it. It cannot commission research on unpatentable molecules. That’s not its job. But if nobody else will either, we end up with a blind spot the size of a Costco supplement aisle.

The most sensible path is straightforward and has nothing to do with deregulation. The NIH should allocate a sliver of its Alzheimer’s budget — call it two percent — to large, definitive trials of repurposed generics that show mechanistic promise. Metformin, lithium, creatine, perhaps a half-dozen others. Total cost would run in the low hundreds of millions, a rounding error next to the amyloid spend. If the results are negative, we close the books and move on. If they’re positive, we hand physicians an evidence base for interventions their patients can actually afford.

That’s not a radical idea. It’s the kind of thing a well-functioning public-health research apparatus does as a matter of course. The fact that we haven’t done it — that a pilot study from Kansas in 2026 feels like a revelation rather than a footnote — tells you something about whose problems the apparatus is organized to solve.

The creatine finding may not hold up. Most pilot studies don’t. But the pattern will recur with other compounds, and the same silence will greet them. The scandal isn’t that a supplement might slow Alzheimer’s. It’s that we’ve built a system where discovering that fact required a small academic team willing to work without a biotech sponsor.

Sources